12 February 2019 | News
The inspection was carried out between January 28 to February 8, 2019
Pharma major Lupin announced the completion of the United States Food and Drug Administration (U.S. FDA) inspection at its Goa manufacturing facility. The inspection was carried out between January 28 to February 8, 2019.
As per the company statement, ”The inspection at the Goa facility closed with 2 observations. The observations are procedural in nature and the Company is confident of addressing them satisfactorily.”
For the financial year ended 31st March, 2018, Lupin’s Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively